Literature DB >> 19095445

DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.

Stephen P East1, Clara Bantry White, Oliver Barker, Stephanie Barker, James Bennett, David Brown, E Andrew Boyd, Christopher Brennan, Chandana Chowdhury, Ian Collins, Emmanuelle Convers-Reignier, Brian W Dymock, Rowena Fletcher, David J Haydon, Mihaly Gardiner, Stuart Hatcher, Peter Ingram, Paul Lancett, Paul Mortenson, Konstantinos Papadopoulos, Carol Smee, Helena B Thomaides-Brears, Heather Tye, James Workman, Lloyd G Czaplewski.   

Abstract

The synthesis and antibacterial activities of three chemotypes of DNA supercoiling inhibitors based on imidazolo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine scaffolds that target the ATPase subunits of DNA gyrase and topoisomerase IV (GyrB/ParE) is reported. The most potent scaffold was selected for optimization leading to a series with potent Gram-positive antibacterial activity and a low resistance frequency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19095445     DOI: 10.1016/j.bmcl.2008.11.102

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

Review 1.  In front of and behind the replication fork: bacterial type IIA topoisomerases.

Authors:  Claudia Sissi; Manlio Palumbo
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 2.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  The challenge of developing robust drugs to overcome resistance.

Authors:  Amy C Anderson; Michael P Pollastri; Celia A Schiffer; Norton P Peet
Journal:  Drug Discov Today       Date:  2011-07-19       Impact factor: 7.851

4.  Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.

Authors:  Neil R Stokes; Helena B Thomaides-Brears; Stephanie Barker; James M Bennett; Joanne Berry; Ian Collins; Lloyd G Czaplewski; Vicki Gamble; Paul Lancett; Alastair Logan; Christopher J Lunniss; Hilary Peasley; Stéphanie Pommier; Daniel Price; Carol Smee; David J Haydon
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

5.  Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.

Authors:  Leslie W Tari; Xiaoming Li; Michael Trzoss; Daniel C Bensen; Zhiyong Chen; Thanh Lam; Junhu Zhang; Suk Joong Lee; Grayson Hough; Doug Phillipson; Suzanne Akers-Rodriguez; Mark L Cunningham; Bryan P Kwan; Kirk J Nelson; Amanda Castellano; Jeff B Locke; Vickie Brown-Driver; Timothy M Murphy; Voon S Ong; Chris M Pillar; Dean L Shinabarger; Jay Nix; Felice C Lightstone; Sergio E Wong; Toan B Nguyen; Karen J Shaw; John Finn
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

6.  Antibacterial Evaluation and Virtual Screening of New Thiazolyl-Triazole Schiff Bases as Potential DNA-Gyrase Inhibitors.

Authors:  Cristina Nastasă; Dan C Vodnar; Ioana Ionuţ; Anca Stana; Daniela Benedec; Radu Tamaian; Ovidiu Oniga; Brînduşa Tiperciuc
Journal:  Int J Mol Sci       Date:  2018-01-11       Impact factor: 5.923

7.  Mannich base limits Candida albicans virulence by inactivating Ras-cAMP-PKA pathway.

Authors:  Satish Kumar Rajasekharan; Chakkaravarthi Kamalanathan; Vinothkannan Ravichandran; Arvind Kumar Ray; Ann Susan Satish; Sucharitha Kannappan Mohanvel
Journal:  Sci Rep       Date:  2018-10-08       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.